OncoMatch/Clinical Trials/NCT03647072

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Is NCT03647072 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including CHOP and CHOP Plus Lanzoprazole for lymphoma.

Phase 3RecruitingSherief Abd-ElsalamNCT03647072Data as of May 2026

Treatment: CHOP · CHOP Plus Lanzoprazole · CHOP Plus Famotidine — The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify